A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3640254 in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2017
At a glance
- Drugs GSK 3640254 (Primary)
- Indications HIV infections
- Focus Adverse reactions; First in man
- Sponsors ViiV Healthcare
- 03 Nov 2017 Status changed from not yet recruiting to recruiting.
- 31 Aug 2017 Planned End Date changed from 24 Jun 2018 to 19 Jul 2018.
- 31 Aug 2017 Planned primary completion date changed from 24 Jun 2018 to 19 Jul 2018.